한글목차

펩티드 및 항응고제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 15억 4,000만 달러에서 2026년에는 17억 달러에 이르고, CAGR 10.0%로 성장할 전망입니다. 지난 수년간의 성장에는 심혈관 질환 발생률 증가, 병원 내 항응고제 보급, 펩타이드 치료제의 임상적 성공, 수술 건수 증가, 혈전증 치료 가이드라인의 확대 등이 주요 요인으로 작용한 것으로 분석됩니다.

펩티드 및 항응고제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 24억 7,000만 달러에 이르고, CAGR은 9.9%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 전 세계 고령화, 혈액응고장애 유병률 증가, 안전성이 높은 항응고요법에 대한 수요 증가, 펩타이드 의약품 파이프라인 확대, 외래 진료에서의 채용 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 펩타이드 계열 치료제 도입 증가, 심혈관 치료에서 항응고제 사용 확대, 표적형 트롬빈 억제제에 대한 수요 증가, 주사제 펩타이드 의약품의 적용 확대, 혈전성 질환 예방에 대한 집중도 강화 등을 들 수 있습니다.

만성 질환의 발생률 증가는 펩타이드 및 항응고제 시장의 확대를 촉진할 것으로 예측됩니다. 만성질환이란 장기간 지속되는 건강 상태를 말하며, 경우에 따라서는 수년 또는 평생 지속될 수도 있습니다. 이러한 증가는 고령화, 부적절한 생활습관, 비만-고혈압-당뇨병 등 위험인자 증가율 증가 등의 요인에 기인합니다. 펩타이드 및 항응고제는 심혈관 질환, 혈전증, 뇌졸중을 치료하고 혈전 예방 및 질병 기전에 대한 정밀한 작용을 통해 환자의 더 나은 치료 결과를 목표로 합니다. 예를 들어, 미국 정부 기관인 질병통제예방센터(CDC)가 지난 5월 발표한 보고서에 따르면, 2022년 심장병과 암으로 인한 사망자 수가 69만 5,547명에 달할 것으로 예상했습니다. 이러한 만성질환의 부담 증가는 펩타이드 및 항응고제 시장의 성장을 견인하고 있습니다.

펩타이드 및 항응고제 분야의 주요 기업들은 경구용 항응고제를 포함한 항응고 치료의 혁신을 우선순위에 두고 효능을 개선하고 환자의 복약 순응도를 높이며 출혈 위험을 최소화하기 위해 노력하고 있습니다. 경구용 항응고제는 혈액 내 응고인자를 억제하여 혈전을 예방하는 경구용 약물입니다. 예를 들어, 2024년 4월 미국 제약회사 카드렌탈 테라퓨틱스(Cadrenal Therapeutics)는 개발 중인 경구용 항응고제 '테칼파린'에 대해 미국 식품의약국(FDA)으로부터 희귀질환 치료제 지정(ODD)을 받았습니다. 테칼파린은 희귀 심혈관 질환 환자에서 혈전으로 인한 심근경색, 뇌졸중, 사망 위험을 줄이기 위한 새로운 가역적 항응고제입니다. 이 ODD는 좌심보조장치(LVAD), 우심보조장치(RVAD), 심실보조장치(VAD), 양심실보조장치, 인공심장 등 이식형 기계식 순환보조장치를 사용하는 환자의 혈전색전증 및 혈전증 예방을 목적으로 합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Peptide and anticoagulant drugs serve as therapeutic agents, with peptide drugs consisting of short chains of amino acids that imitate natural biological molecules, and anticoagulant drugs working to prevent blood clotting by blocking clotting factors. Certain anticoagulants, such as hirudin and bivalirudin, are peptide-derived and directly block thrombin to inhibit thrombosis. These medications play a vital role in managing conditions like deep vein thrombosis, pulmonary embolism, and stroke.

The primary categories of peptide and anticoagulant medications include hormonal, antibiotic, ACE inhibitor, antifungal, and additional types. Hormonal therapies, such as peptide-derived hormones like insulin and GLP-1 analogs, help balance hormone levels to address conditions like diabetes, whereas peptide and anticoagulant drugs deliver precise treatments for chronic illnesses. These medications can be given via multiple routes, such as oral, injectable, or alternative methods, and are available through hospital pharmacies, retail pharmacies, online pharmacies, and more. They serve diverse medical areas, including infectious diseases, gynecology, cancer, diabetes, cardiology, osteoporosis, and beyond. The end-users encompass hospitals, specialty clinics, home care settings, and others.

Tariffs have impacted the peptide and anticoagulant drugs market by increasing the cost of peptide synthesis materials and biologic grade inputs used in injectable drug manufacturing. These effects are most evident in injectable formulations and hospital pharmacy procurement, where quality and supply continuity are critical. Regions such as North America and Europe have experienced higher input costs due to reliance on global peptide and biologics supply chains. Rising tariff related expenses have influenced pricing strategies, procurement planning, and inventory management for anticoagulant therapies. However, tariffs have supported regional manufacturing expansion, expanded local production capacity, and strengthened long term supply chain resilience.

The peptide and anticoagulant drugs market research report is one of a series of new reports from The Business Research Company that provides peptide and anticoagulant drugs market statistics, including peptide and anticoagulant drugs industry global market size, regional shares, competitors with a peptide and anticoagulant drugs market share, detailed peptide and anticoagulant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the peptide and anticoagulant drugs industry. This peptide and anticoagulant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide and anticoagulant drugs market size has grown strongly in recent years. It will grow from $1.54 billion in 2025 to $1.7 billion in 2026 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to rising incidence of cardiovascular diseases, widespread use of anticoagulants in hospitals, clinical success of peptide therapeutics, growth in surgical procedures, expansion of thrombosis treatment guidelines.

The peptide and anticoagulant drugs market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to aging global population, increasing prevalence of blood clotting disorders, growing demand for safer anticoagulant therapies, expansion of peptide drug pipelines, rising adoption in outpatient care. Major trends in the forecast period include rising adoption of peptide-based therapeutics, increasing use of anticoagulants in cardiovascular care, growing demand for targeted thrombin inhibitors, expansion of injectable peptide drug applications, increased focus on preventing thrombotic disorders.

The increasing incidence of chronic diseases is anticipated to fuel expansion in the peptide and anticoagulant drugs market. Chronic diseases are long-term health conditions that endure over prolonged periods, sometimes lasting years or a lifetime. This rise stems from factors like aging populations, poor lifestyle choices, and growing rates of risk factors including obesity, hypertension, and diabetes. Peptide and anticoagulant drugs treat these conditions by addressing cardiovascular diseases, thrombosis, and stroke-working to prevent blood clots and target precise disease mechanisms for better patient results. For instance, in May 2023, reports from the Centers for Disease Control and Prevention, a U.S. government agency, indicated that heart disease and cancer caused 695,547 deaths in 2022. Thus, the growing burden of chronic diseases is propelling the peptide and anticoagulant drugs market forward.

Major companies in the peptide and anticoagulant drugs sector are prioritizing innovations in anticoagulant treatments, including oral anticoagulants, to boost effectiveness, enhance patient adherence, and minimize bleeding risks. An oral anticoagulant is a drug ingested orally that prevents blood clots by blocking clotting factors in the bloodstream. For example, in April 2024, Cadrenal Therapeutics Inc., a U.S.-based pharmaceutical firm, earned Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for tecarfarin, its advanced oral anticoagulant. Tecarfarin serves as a novel, reversible blood thinner intended to lower the risk of heart attacks, strokes, and death from blood clots in patients with rare cardiovascular disorders. The ODD targets the prevention of thromboembolism and thrombosis in patients using implanted mechanical circulatory support devices, such as left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), ventricular assist devices (VADs), biventricular assist devices, and total artificial hearts.

In September 2023, Biosynth-a Switzerland-based supplier of complex chemicals and biological materials-acquired Pepceuticals for an undisclosed sum. The purchase bolsters Biosynth's expertise in developing and producing peptide-based therapeutics and biomaterials. This strategic step strengthens Biosynth's standing in the life sciences field, enabling a wider array of advanced offerings for pharmaceutical and biotech sectors. Pepceuticals Ltd, a UK-based producer of synthetic peptides.

Major companies operating in the peptide and anticoagulant drugs market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., F. Hoffmann-La Roche Ltd, Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Abbott Laboratories, Baxter International Inc., Viatris Inc., Sun Pharmaceutical Industries Limited, Bachem Holding AG, Bharat Serums and Vaccines Limited, Wockhardt Limited, AmbioPharm Inc., Circle Pharma Inc., Teva Pharmaceutical Industries Ltd., Shionogi & Co. Ltd.

North America was the largest region in the peptide and anticoagulant drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and anticoagulant drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide and anticoagulant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide and anticoagulant drugs market consists of sales of peptide-based drugs and heparins. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide And Anticoagulant Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses peptide and anticoagulant drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide and anticoagulant drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide and anticoagulant drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Peptide Drugs; Anticoagulant Drugs; Peptide-Based Anticoagulant Drugs; Synthetic Peptide Drugs; Recombinant Peptide Drugs
• 2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 4) By Application: Infectious Diseases; Gynecology; Cancer; Diabetes; Cardiology; Osteoporosis; Other Applications
• 5) By End-users: Hospitals; Specialty Clinics; Homecare; Other End-users
• Subsegments:
• 1) By Peptide Drugs: Therapeutic Peptides; Hormonal Peptides; Metabolic Peptides; Cardiovascular Peptides; Oncology Peptides
• 2) By Anticoagulant Drugs: Direct Thrombin Inhibitors; Factor Xa Inhibitors; Heparin And Heparin Derivatives; Vitamin K Antagonists
• 3) By Peptide-Based Anticoagulant Drugs: Hirudin And Hirudin Analogues; Bivalirudin; Other Peptide Thrombin Inhibitors
• 4) By Synthetic Peptide Drugs: Solid-Phase Synthesized Peptides; Long-Acting Synthetic Peptides; Modified Synthetic Peptides
• 5) By Recombinant Peptide Drugs: Recombinant Therapeutic Peptides; Recombinant Hormonal Peptides; Recombinant Metabolic Peptides
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bayer AG; Sanofi S.A.; F. Hoffmann-La Roche Ltd; Novartis AG; Novo Nordisk A/S; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Abbott Laboratories; Baxter International Inc.; Viatris Inc.; Sun Pharmaceutical Industries Limited; Bachem Holding AG; Bharat Serums and Vaccines Limited; Wockhardt Limited; AmbioPharm Inc.; Circle Pharma Inc.; Teva Pharmaceutical Industries Ltd.; Shionogi & Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Peptide And Anticoagulant Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Peptide And Anticoagulant Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Peptide And Anticoagulant Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Peptide And Anticoagulant Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Peptide-Based Therapeutics
  • 4.2.2 Increasing Use Of Anticoagulants In Cardiovascular Care
  • 4.2.3 Growing Demand For Targeted Thrombin Inhibitors
  • 4.2.4 Expansion Of Injectable Peptide Drug Applications
  • 4.2.5 Increased Focus On Preventing Thrombotic Disorders

5. Peptide And Anticoagulant Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Cardiology Clinics
• 5.3 Specialty Clinics
• 5.4 Ambulatory Surgical Centers
• 5.5 Homecare Settings

6. Peptide And Anticoagulant Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Peptide And Anticoagulant Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Peptide And Anticoagulant Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Peptide And Anticoagulant Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Peptide And Anticoagulant Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Peptide And Anticoagulant Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Peptide And Anticoagulant Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Peptide And Anticoagulant Drugs Market Segmentation

• 9.1. Global Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Peptide Drugs, Anticoagulant Drugs, Peptide-Based Anticoagulant Drugs, Synthetic Peptide Drugs, Recombinant Peptide Drugs
• 9.2. Global Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable, Other Routes Of Administration
• 9.3. Global Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
• 9.4. Global Peptide And Anticoagulant Drugs Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, Other Applications
• 9.5. Global Peptide And Anticoagulant Drugs Market, Segmentation By End-users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Homecare, Other End-users
• 9.6. Global Peptide And Anticoagulant Drugs Market, Sub-Segmentation Of Peptide Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Therapeutic Peptides, Hormonal Peptides, Metabolic Peptides, Cardiovascular Peptides, Oncology Peptides
• 9.7. Global Peptide And Anticoagulant Drugs Market, Sub-Segmentation Of Anticoagulant Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Direct Thrombin Inhibitors, Factor Xa Inhibitors, Heparin And Heparin Derivatives, Vitamin K Antagonists
• 9.8. Global Peptide And Anticoagulant Drugs Market, Sub-Segmentation Of Peptide-Based Anticoagulant Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hirudin And Hirudin Analogues, Bivalirudin, Other Peptide Thrombin Inhibitors
• 9.9. Global Peptide And Anticoagulant Drugs Market, Sub-Segmentation Of Synthetic Peptide Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Solid-Phase Synthesized Peptides, Long-Acting Synthetic Peptides, Modified Synthetic Peptides
• 9.10. Global Peptide And Anticoagulant Drugs Market, Sub-Segmentation Of Recombinant Peptide Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Recombinant Therapeutic Peptides, Recombinant Hormonal Peptides, Recombinant Metabolic Peptides

10. Peptide And Anticoagulant Drugs Market Regional And Country Analysis

• 10.1. Global Peptide And Anticoagulant Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Peptide And Anticoagulant Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Peptide And Anticoagulant Drugs Market

• 11.1. Asia-Pacific Peptide And Anticoagulant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Peptide And Anticoagulant Drugs Market

• 12.1. China Peptide And Anticoagulant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Peptide And Anticoagulant Drugs Market

• 13.1. India Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Peptide And Anticoagulant Drugs Market

• 14.1. Japan Peptide And Anticoagulant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Peptide And Anticoagulant Drugs Market

• 15.1. Australia Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Peptide And Anticoagulant Drugs Market

• 16.1. Indonesia Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Peptide And Anticoagulant Drugs Market

• 17.1. South Korea Peptide And Anticoagulant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Peptide And Anticoagulant Drugs Market

• 18.1. Taiwan Peptide And Anticoagulant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Peptide And Anticoagulant Drugs Market

• 19.1. South East Asia Peptide And Anticoagulant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Peptide And Anticoagulant Drugs Market

• 20.1. Western Europe Peptide And Anticoagulant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Peptide And Anticoagulant Drugs Market

• 21.1. UK Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Peptide And Anticoagulant Drugs Market

• 22.1. Germany Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Peptide And Anticoagulant Drugs Market

• 23.1. France Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Peptide And Anticoagulant Drugs Market

• 24.1. Italy Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Peptide And Anticoagulant Drugs Market

• 25.1. Spain Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Peptide And Anticoagulant Drugs Market

• 26.1. Eastern Europe Peptide And Anticoagulant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Peptide And Anticoagulant Drugs Market

• 27.1. Russia Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Peptide And Anticoagulant Drugs Market

• 28.1. North America Peptide And Anticoagulant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Peptide And Anticoagulant Drugs Market

• 29.1. USA Peptide And Anticoagulant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Peptide And Anticoagulant Drugs Market

• 30.1. Canada Peptide And Anticoagulant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Peptide And Anticoagulant Drugs Market

• 31.1. South America Peptide And Anticoagulant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Peptide And Anticoagulant Drugs Market

• 32.1. Brazil Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Peptide And Anticoagulant Drugs Market

• 33.1. Middle East Peptide And Anticoagulant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Peptide And Anticoagulant Drugs Market

• 34.1. Africa Peptide And Anticoagulant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Peptide And Anticoagulant Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Peptide And Anticoagulant Drugs Market Regulatory and Investment Landscape

36. Peptide And Anticoagulant Drugs Market Competitive Landscape And Company Profiles

• 36.1. Peptide And Anticoagulant Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Peptide And Anticoagulant Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Peptide And Anticoagulant Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

37. Peptide And Anticoagulant Drugs Market Other Major And Innovative Companies

• Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Abbott Laboratories, Baxter International Inc., Viatris Inc., Sun Pharmaceutical Industries Limited, Bachem Holding AG, Bharat Serums and Vaccines Limited, Wockhardt Limited, AmbioPharm Inc., Circle Pharma Inc., Teva Pharmaceutical Industries Ltd., Shionogi & Co. Ltd.

38. Global Peptide And Anticoagulant Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Peptide And Anticoagulant Drugs Market

40. Peptide And Anticoagulant Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Peptide And Anticoagulant Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Peptide And Anticoagulant Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Peptide And Anticoagulant Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer